Phase 2 study of first‐line pembrolizumab monotherapy in elderly patients with non‐small‐cell lung cancer expressing high PD‐L1

BACKGROUND: Pembrolizumab is the recommended first‐line therapy for patients with advanced non‐small‐cell lung cancer (NSCLC) and a programmed death ligand‐1 (PD‐L1) tumor proportion score (TPS) of ≥50% without driver mutations. However, its efficacy and safety for patients ≥75 years have not been p...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Takeshi, Fujitaka, Kazunori, Suzuki, Tomoko, Hamai, Kosuke, Matsumoto, Naoko, Matsumura, Mirai, Isoyama, Shoko, Ueno, Sayaka, Mito, Mineyo, Yamaguchi, Kakuhiro, Sakamoto, Shinjiro, Kawano, Reo, Masuda, Ken, Nishino, Ryohei, Ishikawa, Nobuhisa, Yamasaki, Masahiro, Hattori, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161325/
https://www.ncbi.nlm.nih.gov/pubmed/35488720
http://dx.doi.org/10.1111/1759-7714.14428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161325/
https://www.ncbi.nlm.nih.gov/pubmed/35488720
http://dx.doi.org/10.1111/1759-7714.14428

Ejemplares similares